What drugs should be used with erlotinib to treat pancreatic cancer?

When erlotinib is used to treat pancreatic cancer, it is often used in combination with other drugs to improve the therapeutic effect. Combination therapy with erlotinib and gemcitabine is a common regimen for the treatment of pancreatic cancer. Gemcitabine, as a broad-spectrum anti-tumor drug, has been widely used in the chemotherapy of pancreatic cancer. When erlotinib is used in combination with gemcitabine, it can exert a synergistic effect to jointly inhibit the proliferation and metastasis of tumor cells. This combination therapy has been confirmed by multiple clinical studies to extend the survival time and improve the quality of life of patients with pancreatic cancer.

According to relevant research data, erlotinib combined with gemcitabine in the treatment of pancreatic cancer can significantly improve the progression-free survival (PFS) and overall survival (OS) of patients. For example, in one study, patients who received the combination therapy had months longer PFS and improved OS compared with those who received gemcitabine alone. In addition, combination therapy can also improve the disease control rate (DCR) and reduce patient suffering.

Although erlotinib combined with gemcitabine has certain efficacy in the treatment of pancreatic cancer, safety issues also require attention. This combination therapy may increase the risk of adverse reactions such as rash, diarrhea, nausea, and vomiting. However, these adverse effects are mostly tolerable and can be alleviated with appropriate supportive care. When doctors use combination therapy, they will make adjustments based on the patient's specific situation to ensure the safety and effectiveness of the treatment.

In addition to gemcitabine, erlotinib may also be used in combination with other drugs to treat pancreatic cancer. For example, some studies have shown that the combination of erlotinib and targeted drugs such as everolimus may have better anti-tumor effects. However, the specific efficacy and safety of these combination regimens need to be confirmed by further clinical studies.